ABSTRACT. This study investigated the induced immune tolerance of autoantigen dendritic cells (imDCs) in homogenic lupus mice to support the use of dendritic cell treatment against autoimmune diseases, such as systemic lupus erythematosus. A lupus mouse was used to model based on in vitro cell culture. An immunohistochemistry assay was used to assess CD8 + cells in mouse spleen lymphocytes was detected by flow cytometry, whereas the kidney was directly measured by immunofluorescence. After the injection of mouse antigen loaded bone marrow-derived antigen imDCs with a homogenetic background, mouse nucleoprotein immune with a homogenetic background was carried out. The results were compared against the simple mouse nucleoprotein immune model with a homogenic background. The 24-h urine protein, serum antinuclear antibody and anti-ds-DNA antibodies of the simple mouse model were lower compared to group S1. The CD4 + CD25
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INTRODUCTION
The main manifestations of systemic lupus erythematosus (SLE) are the production of various autoantibodies, nephritis, arthritis, and other types of systemic multi-system damage, all of which lead to high mortality. Recently, dendritic cells (DCs) have been identified as the most powerful antigen-presenting cells (APCs). Furthermore, only APCs are able to activate initial immune responses (termed imDCs). ImDCs are able to 1) uptake and process antigens, 2) cause non-response and apoptosis of specific T-cells, 3) generate regulatory T cells, and 4) induce immune tolerance. Research of DC treatments that might effectively counteract SLE has only just begun; however, the pathogenesis of SLE and the mechanisms that some drugs act on SLE indicate a close relationship between DCs and the pathogenesis of SLE. In this experiment, imDCs loaded autoantigen ingredients were inserted in vitro into homogenic lupus mice to induce immune tolerance, and to determine whether it is possible to alleviate the symptoms of SLE.
MATERIAL AND METHODS

Experimental animals
SPF healthy BALB/c mice (6 to 8 weeks olds), weighing 18-20 g, were kept in a clean grade environment. The mice were kept at a density of 5 individuals per box. The temperature ranged from 20° to 24°C and the relative humidity ranged from 50 to 60%. Formula feed was given to the mice ad libitum, along with an unlimited water supply. The animals were provided by the Experimental Animal Center of Hubei Province, China. This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health, China. The animal use protocol was reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of the Yangtze River Shipping General Hospital, China.
Immune models
S1: Homologous BALB/c mouse nucleoprotein was extracted for use as an antigen. The extracted nucleoprotein and corresponding equal F's immune adjuvant were mixed to obtain a full emulsion. The antigen concentration was 1 mg/mL. Mice were then immunized by injecting 50 μL of the antigen intramuscularly into each hind limb tibialis anterior muscle, with a total dose of 100 μg per mouse. Before the intramuscular injection, 100 μL 0.5% bupivacaine was injected into the mice to cause the selective destruction of muscle fibers and regeneration of myoblasts, which would help the uptake of the antigen and produce the best immune response. The antigen injections were given over a 3-week interval, with all animals being immunized 4 times. S2: One week before each immune injection, BALB/c mouse bone marrow-derived autoantigen loaded imDCs with a homogenetic background were input via the tail vein of mice.
S3: Mice received an injection of the same volume as the other mice, but PBS was used. S4: This group was the control. Nucleoprotein and imDCs were extracted from 4 BALB/c mice with homogenetic backgrounds in the S1 and S2 groups.
Separation and purification of BALB/c mouse imDCs
Following the method of Xie et al. (2009) , BALB/c mice with homogenetic background were sacrificed by cervical dislocation, and placed in 75% ethanol for 5 min. The mouse femur was removed aseptically, and placed in cold PBS. The muscle tissue was removed in a sterile console, and washed 3 times with cold PBS. The marrow cavity was repeatedly flushed until the cavity turned white. The bone marrow was washed and collected after the break-up of the erythrocytes. The collected substrate was transformed into a 1 x 10 6 /mL bone marrow cell suspension by RPMI 1640 (fetal bovine serum purchased from GIBCO, Pascagoula, MS, USA) containing 10% fetal calf serum, 20 ng/mL rmGM-CSF, and 10 ng/ mL rmIL-4 (all purchased from PeproTech, Wellesley, MA, USA). The resultant solution was seeded into 24-well plates, with 1 mL in each well. The plates were then placed at 37°C in a 5% CO 2 incubator culture for 1 day. The following day, half of the medium was changed, and a full amount of cytokines was added. Under an inverted phase contrast microscope, changes in the morphology and number of DCs were observed. The DCs exhibited a semi-suspended growth state and could be collected by repeated pipetting. The DCs from random wells were collected and pipetted into cell debris by triple-distilled water, and added to the DCs that had been cultured for 7 days. The resultant solution was co-incubated for 48 h, and then all cells were harvested (Buelens et al., 1997) . The survival rate of imDCs was assessed by AO-PI staining. Specifically, the cells were assessed under a fluorescent microscope at a 490-nm excitation light using a 510-nm grating filter, and were differentiated based on color. Endoscopic green cells represented living cells, while red cells represented dead cells.
Injection of imDCs
Autoantigen loaded imDCs of BALB/c mice with a homogenetic background were collected. The cell density was adjusted to 1 x 10 8 /mL. The mouse was fixed. Then, after the preparation and disinfection of the tail skin, a proximal tourniquet ligation was made around the entire distal tail vein. Then, a 1-mL disposable syringe was used to puncture the tail vein, and the needle was withdrawn when the blood entered the needle, and the tourniquet was relaxed. An intravenous injection of 0.1 mL cultured cell suspension was given to mice 1 week before each nucleoprotein injection.
Protein determination
Sulfosalicylic acid-sodium sulfate turbidimetry was applied to detect the proteins in the urine of mice for 24 h.
ELISA
The ELIZA kit (Sigma, St. Louis, MO, USA) was used to detect mice serum antinuclear antibody (ANA) and anti-ds-DNA antibodies after the last immunization (at 22 days). The analyses were conducted using the collected blood (Xie and Lin, 2011) .
CD4 +
CD25
+ cell ratios
After the last immunization at 22 days, the mouse spleen was removed. The mice were sacrificed, and then immersed in 75% ethanol for 1-2 min. In laminar flow, the skin was carefully cut and fixed. Then, the mouse spleen was removed from the abdominal cavity through a section of the abdomen. The aseptic technique used here should be noted.
About 4-5 mL EZ-Sep Mouse 1X lymphocyte separation medium (Dakota Biotechnology Co., Ltd.) was added to a 60-mm Petri dish, with a fixed nylon mesh. Then, the mouse spleen was gently ground by a syringe piston to transfer the dispersed single cells into the lymphocyte separation medium through the nylon mesh. The separation liquid with suspended spleen cells was transferred to a centrifuge tube, and about 1 mL RPMI 1640 medium with 10% fetal calf serum was added to cover the liquid. The liquid (800 g) was centrifuged for 30 min, at which point the lymphocytes floated up and gathered under the upper RPMI 1640 layer. The lymphocyte layer was sucked out. Then, 10 mL RPMI 1640 medium was added to the lymphocytes, and 250 g was centrifuged for 10 min. A volume of 500 μL PBS was used to resuspend the spleen lymphocytes. A volume of 100 μL of this mixture was added to each 5 μL anti-mouse CD4-PE and anti-mouse CD25-FITC, and to each 5 μL anti-mouse lgG1-PE and anti-mouse lgG2-FITC (eBioscience, San Diego, CA, USA). The solutions were incubated in the dark for 20 min. Then, the mouse spleen lymphocytes from each group were subjected to flow cytometry to measure the ratio of CD4 + CD25 + cells.
CD8 + , CD4 + cell ratios
After the final immunization (at 22 days), the mouse spleen was removed. The spleen was fixed in 10% formalin solution for 72 h. After dehydration in alcohol (xylene), the spleen was embedded in paraffin, and then dewaxed, with sections of about 2 μm thick being cut. A volume of 0.01 M PBS, pH 7.4 was used to wash the sections 3 times (3 min for each). High pressure repaired the antigen. A volume of 2000 mL 0.01 M citrate buffer was placed in a stainless steel pressure cooker and boiled. The slides were then placed in the solution, which was heated for a further 1.5 min. The slides were then cooled and washed for 5 min with PBS 3 times. A volume of 3% hydrogen peroxide solution was added to the mixture at room temperature, and left to rest for 20 min. Then, the washing step was repeated. A volume of 50 μL primary antibody (anti-mouse CD4 and CD8 was purchased from eBioscience), which was diluted at a ratio of 1:40 in PBS, was dropped onto each slide. The slides were subject to moist chamber incubation at 37° C for 2 h. Then, the washing step was repeated again. A volume of 50 μL secondary antibody (ready to use) [SuperPie Ture polymer detection (zymed packaging)] was dropped onto each slide, and incubated at room temperature for 30 min. The washing step was repeated. DAB reagent was added to provide color, with the reaction requiring about 10 min. After flushing with water, hematoxylin, and pan-blue, the slices were dried and mounted on neutral gum.
Immunofluorescence detection of mouse kidney tissue
After the final immunization (at 22 days), the kidneys were removed. The unilateral kidneys of mice from each group were collected, wrapped in gauze, and placed in an ice box to obtain quick frozen slices (using a frozen section machine; SLEE, Zeiss, Germany). Five slices were prepared from each specimen, each with a thickness of about 2 μm. The tissue slices were mounted onto glass slides. Then, 10 μL rabbit anti-mouse IgG or IgM fluorescent antibody was dropped onto the slides (Wuhan Boster Biological Engineering Co., Ltd.) (1:40 dilution, PBS) to stain for 30 min. The washing step was repeated and the slides were covered. The slides were then observed under a fluorescence microscope.
Statistical analysis
Statistical analysis was carried out using SPSS version 12.0 for Windows (SPSS, Chicago, IL, USA). Because all experimental groups had a normal distribution, intergroup differences were assessed using parametric statistical methods; specifically, paired independent sample t-tests and a one-way analysis of variance (ANOVA). Data are reported as means ± standard deviation. Probabilities less than 5% (P < 0.05) were considered to be statistically significant. All experiments were repeated a minimum of 3 times.
RESULTS
AO-PI staining of imDCs
The imDC survival rate was assessed by AO-PI staining. The colors were observed under a fluorescent microscope with a 490-nm excitation light and a 510-nm grating filter. Microscopic green cells were regarded as living cells, while red cells represented dead cells. A cell survival rate of more than 90% was obtained (Figure 1) .
Detection of 24-h urine protein levels in mice
Homogeneity of the variance test was performed in SPSS13.0. The homogeneity of variance was verified (W = 1.709, P = 0.182) for the mouse urine levels. ANOVA indicated significant differences among the experimental groups (F = 33164.524, P = 0.000).
Data showed that S3 and S4 experimental groups had the lowest means for the 24-h urine protein levels, followed by the S2 group, with the S1 group having the highest levels. The SNK test was used for pairwise comparison among groups. The SNK test placed S3 and S4 experimental groups in the same sub-group, while S1 and S2 were in separate sub-groups. There was no difference between S3 and S4 experimental groups. There was a difference between S1 and S2 groups. S1 and S2 groups were different compared to S3 and S4 groups. The greatest difference was obtained for the S2 group with the S3 and S4 groups (Table 1 and Figure 2 ). Table 1 . Twenty-four-hour urine protein in mice, anti-ds-DNA antibody, and antinuclear antibody (ANA).
Data are reported as means ± SD for 10 animals in each group.
Detection of the serum anti-ds-DNA antibody
Homogeneity of the variance test was performed in SPSS13.0. The homogeneity of variance of the serum anti-ds-DNA antibody was verified (W = 1.297, P = 0.29). ANOVA indicated significant differences among the 4 groups (F = 445.93, P = 0.000).
Data showed that S3 and S4 groups had the lowest mean anti-ds-DNA antibodies, followed by S2, with S1 having the highest levels. The SNK test was used for pairwise comparison among groups. The SNK test indicated that S3 and S4 were in the same sub-group, while S1 and S2 were in 2 separate sub-groups. There was no difference between S3 and S4 groups. There was a difference between S1 and S2 groups. S1 and S2 groups were different compared to S3 and S4 groups. The greatest difference was obtained for the S2 group with S3 and S4 groups (Table 1 and Figure 2 ).
Detection of mouse serum ANA
Homogeneity of the variance test was performed in SPSS13.0. The homogeneity of variance verified the presence of mouse serum ANA (W = 0.14, P = 0.935). ANOVA indicated significant differences among the 4 groups (F = 278.619, P = 0.000).
Data showed that S3 and S4 groups had the lowest mean ANA of all the groups, followed by the S2 group, with the S1 group having the highest levels. The SNK test was used for pairwise comparison among groups. The SNK test indicated that S3 and S4 groups were in the same sub-group, while S1 and S2 were in 2 separate sub-groups. There was no difference between S3 and S4 groups. There was a difference between S1 and S2 groups. S1 and S2 groups were different compared to S3 and S4 groups. The greatest difference was obtained for the S2 group with the S3 and S4 groups (Table 1 and Figure 2 ).
CD4 +
CD25
+ cell ratios of mouse spleen cells
The S1 group had a lower CD4 + CD25 + cell ratio compared to S2, S3, and S4 groups. While the S2 group received additional treatment prior to the injections, it had a higher ratio compared to S3 and S4 groups (Figure 3 ).
CD4 + , CD8 + cell ratios of mouse spleen cells (Miller et al., 2004)
The S1 group had a lower CD4 + cell ratio compared to S2, S3, and S4 groups. While the S2 group received additional treatment prior to the injections, it had a lower ratio compared to S3 and S4 groups (Figure 4) .
The S1 group had a higher CD8 + cell ratio compared to S2, S3, and S4 groups. While the S2 group received additional treatment prior to the injections, it had a higher percentage compared to S3 and S4 groups ( Figure 5 ).
Immunofluorescence of the mice kidney tissue
The glomerulus of S1 mice had IgG and IgM immune complex deposition, along with glomerular contours. The glomerulus of S2 mice had a visible but weak fluorescence. The glomerular contours of S3 and S4 mice could not be observed, with a small amount of nonspecific weak fluorescence (Figure 6 ). 
DISCUSSION
Recent research has confirmed the important role of DCs in the immune system, along with their ability to suppress tumors; hence, research in this area has become a major focus of immunology studies and related fields. In addition, the immune tolerance of imDCs is also receiving major attention. In-depth studies of DCs have indicated the presence of a complex and sophisticated adjustment system that forms part of the major immunomodulatory system (Banchereau and Steinman, 1998) . DCs have several major characteristics. First, the DC-mediated immune process is a precise and rigorous process, which involves the timely and accurate migration of DCs to draining lymph nodes, forming the basis of the body's normal immune response. The presence of undesired factors, lead to abnormal migration, producing a pathological immune response. Second, DCs are regulated by cytokines, chemokines, and chemo-attractants and their corresponding ligands, in addition to hormones, proteins, and bacterial products. DCs serve as immune promoters or inhibitors, and are involved in various synergistic or antagonistic activities. Under certain conditions, DCs have contradictory effects. Third, DC adjustment is very complex. For instance, while many trials and studies have demonstrated that many factors affect the activity of DCs, detailed information about the involved mechanisms remains unclear. Fourth, DCs participate in the rejection of some tumors, or escape processes. Recent research has demonstrated the role of DCs in autoimmune diseases; however, the exact mechanisms require further study. Therefore, future research should focus on elucidating the mechanisms of action of various DC factors, including their synergistic and antagonistic modes, pathways, and mechanisms, as well as obtaining details about how their actions are adjusted under different physiological conditions. For instance, the mechanisms of action under different pathological states require clarification to better explain the impacts of various harmful factors on DCs.
Clinical research that focuses on how to treat a variety of immune diseases and a variety of infections through the promotion or suppression of DCs is also vital. Studies to generate vaccines to obtain immunity against tumors have been initiated using the biological functions and migration characteristics of DCs. At present, imDCs have become the major focus for addressing autoimmune diseases (Bluestone et al., 2007) . ImDCs express low levels of major histocompatibility complex MHC II molecules, co-stimulatory molecules, and adhesion molecules. Each DC expresses about 1 x 10 6 MHC II molecules. In vitro studies of DCs in mixed lymphocyte culture (MLC) exhibit a weak capacity to stimulate a mixed lymphocyte reaction (MLR). In addition, DCs exhibit a strong capacity for antigen uptake and processing, without altering the ability of antigens. After the uptake of antigens or after a certain stimulus (i.e., inflammatory signals), imDCs differentiate and mature, with each cell expressing about 7 x 10 6 MHC II molecules. This phenomenon significantly enhances co-stimulatory molecules and adhesion molecules. In vitro MLC has a strong stimulatory ability on MLR; however, the uptake and processing ability of antigens is significantly reduced (Henrickson et al., 2008) . It was first confirmed that DCs induce immune tolerance in the central self-tolerance. Existing studies show that the injection of allogeneic DCs into the thymus of newborn mice induces immune tolerance (Michaels et al., 2005) . Similar results were obtained in studies of bone marrow chimeras and transgenic mice. The immune tolerance obtained from thymic allogeneic antigen injection appears to depend on DCs in the thymus. In addition, donor bone marrow-derived DCs combined with allogeneic peptide-pulsed thymic injection might induce the organ immune tolerance of anti-donor lymphocyte-positive recipients (Ali et al., 2000) . The body's autoantigens are able to reach the thymus through the blood circulation. The central immune tolerance of T-cells is induced by the presentation of thymus DCs. Peripheral blood DCs might also carry foreign antigens, which enter the thymus and play a role in the central tolerance of certain foreign antigens in the thymus. The peripheral tolerance effects of DCs are usually mediated by imDCs and might also depend on the functioning of a certain DC subset. ImDCs show a low expression of co-stimulatory molecules, and (like autoantigens) cannot activate T-cells when in the peripheral lymphoid tissues. However, DCs might also induce Tcell anergy or cause auto-tolerance (Gonzalez-Rev et al., 2006) .
ImDCs and inhibitory DC subsets also induce regulatory/suppressor T-cells to clear immune reactivity T-cells. ImDCs also produce IL-10 and TGF-β cytokines to suppress immune reactive T-cells directly, enabling immune tolerance (den Haan et al., 2007) . ImDCs capture antigens and place them on the effector cell surface (MHC molecules), in addition to engulfing and processing apoptotic cells. Apoptotic cells are effectively captured by DCs, resulting in DCs inducing a weakened inflammatory response function, which facilitates antigen-specific unresponsiveness. The uptake of apoptotic cells does induce inflammation or their transformation into mature cells. In addition, DCs are able to handle and present polypeptides from apoptotic cells (Selenko-Gebauer et al., 2003) . In homeostasis, DCs are targeted towards infusing the apoptotic leukocytes of the donor; hence, the donor might be able to produce regulatory DCs selectively in vivo, within the framework of a cell transplantation therapy program. However, donor leukocytes must be obtained that are in homeostasis, with the injection being carried out in the first few days. This type of program could be applied to a living donor organ transplant (Ferguson et al., 2002) .
In animal models, bone marrow cells receive a low-dose of GM-CSF, which cultivates experimental myeloid imDCs and induces the production of antigen-specific T cell hyporesponsiveness in vitro. Selenko-Gebauer et al. (2003) found that, in the imDC membrane, B7 family molecules PD-L1 and PD-L2 provide a weak co-stimulatory signal that induces T cell anergy. In such cases, cytokine-stimulated-cultured donor myeloid imDCs in vitro are transplanted into the recipient's body to extend graft survival time. Th1 and Th2 cells produce mutual inhibitory cytokines (Billiard et al., 2006) . ImDCs secrete IL-10, TGF-β, and CTLA-Ig to induce Th1/Th2 imbalance (Bank, 1988; Renkl et al., 2005) . ImDCs of the IL-10 loaded plasmid immune rat are able to downregulate MHC class II molecules and co-stimulatory molecules. The infusion of such imDCs to autoimmune myocarditis rats enhances myocardial function, by causing peripheral blood T cells to become more skewed towards skewed Th2 (Murdoch et al., 2004; Kim et al., 2005) . Another study showed that bone marrow imDCs of IL-10 immunized BALB/c mice reduce the ability of DCs to stimulate Th1 and Th2 proliferations, but do not affect the Th2 immune response (O'Connell et al., 2002) .
In the current experiment, the bone marrow cells of BALB/c mice with autologous were lysed to extract the self-antigens of the mice as an antigen substance. Immunohistochemical and electron microscopy observations after DCs self-antigen loading confirmed that DCs are able to present self-antigens. Nucleoprotein immune was carried out after injecting the mouse bone marrow-derived imDCs loaded mouse antigen with the same genetic background. The 24-h urinary protein levels were lower for nucleoprotein immune mice compared to the simple lupus mouse (Satoh et al., 2000; Decker et al., 2005) . Serum ANA and anti-ds-DNA antibody levels were lower in the former compared to the latter. In spleen cells, the CD4 + CD25
+ cell ratio was higher in the S2 compared to the S1. In the spleen lymphocytes, the CD8 + lymphocyte levels were lower in the S2 compared to the S1, whereas CD4 + lymphoid cell levels were higher. The observed changes after autoantigen uptake, prompted imDCs to induce immune tolerance through reinfusion, which might potentially prevent or mitigate SLE-like illnesses. This study has identified the basal mechanisms of DC vaccines, which might be used to treat and prevent SLE.
